Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain

International Journal of Pharmaceutics

Volumn 275, Issue 1-2, 2004, Pages 85-96

  Zhang, Qizhi ^a   Jiang, Xinguo ^a   Jiang, Wenming ^a   Lu, Wei ^a   Su, Lina ^a   Shi, Zhenqi ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Brain targeting; Intranasal delivery; Microemulsion; Nimodipine; Olfactory pathway; Solubilization

Indexed keywords

CREMAPHOR RH 40; CREMOPHOR; LABRAFIL M 1944CS; LABRASOL; MAISINE 35 1; MYRISTIC ACID ISOPROPYL ESTER; NIMODIPINE; NONIONIC SURFACTANT; OIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; MALE; MICROEMULSION; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; ANURA; BRAIN; CALCIUM CHANNEL BLOCKERS; EMULSIONS; ETHANOL; INJECTIONS, INTRAVENOUS; MALE; NASAL MUCOSA; NIMODIPINE; OLFACTORY BULB; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SOLVENTS; SURFACE-ACTIVE AGENTS; WATER;

EID: 1842789813     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.01.039     Document Type: Article

References (25)

1. Behl C.R., Pimplaskar H.K., Sileno A.P., deMeireles J., Romeo V.D. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Deliv. Rev. 29:1998;89-116.
2. Blardi P., Urso R., De Lalla A., Volpi L., Perri T.D., Auteri A. Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin. Pharmacol. Ther. 72:2002;556-561.
3. Chou K.J., Donovan M.D. Distribution of antihistamines into the CSF following intranasal delivery. Biopharm. Drug Dispos. 18:1997;335-346.
4. Chow H.H.S., Chen Z., Matsuura G.T. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci. 88:1999;754-758.
5. Dahlin M., Björk E. Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of rats. Int. J. Pharm. 195:2000;197-205.
6. Gao Z.G., Choi H.G., Shin H.J., Park K.M., Lim S.J., Hwang K.J., Kim C.K. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int. J. Pharm. 161:1998;75-86.
7. Gelmers H.J. Calcium-channel blockers in the treatment of Migraine. Am. J. Cardiol. 55:1985;139B-143B.
8. Glertlova M., Ondrias K. Nifedipine and nimodipine solubility in the presence of diheptanoyl phosphatidylcholine. Pharmazie. 47:1992;861-863.
9. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11:2000;1-18.
10. Jiang X.G., Cui J.B., Fang X.L., Wei Y., Xi N.Z. Toxicity of drugs on nasal mucocilia and the method of its evaluation. Acta Pharm. Sin. 30:1995;848-853.
11. Kale N.J., Allen L.V. Studies on microemulsions using Brij 96 as surfactant and glycerin, ethylene glycol and propylene glycol as cosurfactants. Int. J. Pharm. 57:1989;87-93.
12. Kim C.K., Ryuu S.A., Park K.M., Lim S.L., Hwang S.J. Preparation and physiochemical characterization of phase inverted water/oil microemulsion containing cyclosporin A. Int. J. Pharm. 147:1996;131-134.
13. Langley M.S., Sorkin E.M. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic. Drugs. 37:1989;669-699.
14. Li L., Nandi I., Kim K.H. Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int. J. Pharm. 237:2002;77-85.
15. Liang, W.Q., Fang, X.L., Gao, S., Deng, S.H., Liu, J.P., Jiang, X.H., Li, G., Cheng, G., 2003. Biopharmaceutics and Pharmacokinetics, 2nd ed. People's Medical Publishing House, Beijing.
16. Malcolmson C.M., Lawrence J. A comparsion of the incorporation of model steroids into non-ionic micellar and microemulsion systems. J. Pharm. Pharmacol. 45:1993;141-143.
17. Muck W., Bode H. Bioanalytics of nimodipine - an overview of methods. Pharmazie. 49:1994;130-139.
18. Muck W., Breuel H.P., Kuhlmann J. The influence of age on the pharmacokinetics of nimodipine. Int. J. Clin. Pharmacol. 34:1996;293-298.
19. Pantoni L., Rossi R., Inzitari D., Bianchi C., Beneke M., Erkinjuntti T., Wallin T. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J. Neurol. Sci. 175:2000;124-134.
20. Proctor D.F. The upper airways. I. Nasal physiology and defence of the lungs. Am. Rev. Respir. Dis. 115:1977;97-129.
21. Rameis H. Principles of the pharmacokinetics and pharmacodynamics of calcium anatagonists. Wien Med. Wochenschr. 143:1993;490-500.
22. Warisnoicharoen W., Lansley A.B., Lawrence M.J. Nonionic oil-in-water microemulsions: the effect of oil type on phase behaviour. Int. J. Pharm. 198:2000;7-27.
23. Yoshida A., Yamamoto M., Iloh T., Irie T., Hirayama F., Uekama K. Utility of 2-hydroxypropyl-β-cyclodextrin in an intramuscular injectable preparation of nimodipine. Chem. Pharm. Bull. 38:1990;176-179.
24. Yuan J. Estimation of variance for AUC in animal studies. J. Pharm. Sci. 82:1993;761-763.
25. Zhang J.T. Altered calcium homeostasis in brain aging and senile dementia, new approach to treat Alzheimer's disease. Yao Xue Xue Bao. 28:1993;641-646.